ZYME Stock Price
ZYME
ZYME stock price is $29.18 (-5.69% on the day), giving ZYME a market cap of $2.18B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
ZYME Stock Overview
- Price
- $29.18
- Previous close
- $30.94
- Open
- $30.85
- Market cap
- $2.18B
- 1-year price target
- $41.21
- MarketXLS Rank
- 68
About ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZYME | $29.18 | -5.7% | 844.29K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |